1
项与 Melanoma vaccine(Avanir Pharmaceuticals, Inc.) 相关的临床试验A Randomized Phase II Study of IL-2 With or Without an Allogeneic Large Multivalent Immunogen (LMI) Vaccine for the Treatment of Stage IV Melanoma
RATIONALE: Aldesleukin may stimulate the white blood cells to kill tumor cells. Vaccines may help the body build an effective immune response to kill tumor cells. Giving aldesleukin together with vaccine therapy may kill more tumor cells. It is not yet known whether aldesleukin is more effective with or without vaccine therapy in treating melanoma.
PURPOSE: This randomized phase II trial is studying how well aldesleukin works when given with or without vaccine therapy in treating patients with stage IV melanoma.
100 项与 Melanoma vaccine(Avanir Pharmaceuticals, Inc.) 相关的临床结果
100 项与 Melanoma vaccine(Avanir Pharmaceuticals, Inc.) 相关的转化医学
100 项与 Melanoma vaccine(Avanir Pharmaceuticals, Inc.) 相关的专利(医药)
100 项与 Melanoma vaccine(Avanir Pharmaceuticals, Inc.) 相关的药物交易